Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) shares traded down 2.7% on Monday . The stock traded as low as $6.94 and last traded at $6.93. 83,048 shares changed hands during trading, a decline of 93% from the average session volume of 1,115,473 shares. The stock had previously closed at $7.12.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. Wedbush reaffirmed an "outperform" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Bank of America reduced their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. The Goldman Sachs Group cut their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday, March 25th. Needham & Company LLC reissued a "buy" rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $32.29.
Check Out Our Latest Research Report on Day One Biopharmaceuticals
Day One Biopharmaceuticals Stock Up 1.2 %
The firm has a market cap of $693.27 million, a P/E ratio of -6.64 and a beta of -1.24. The business has a fifty day moving average of $8.82 and a 200 day moving average of $11.81.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million. Research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.
Insider Activity at Day One Biopharmaceuticals
In other news, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. This represents a 10.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeremy Bender sold 12,048 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,064 shares of company stock worth $251,925 over the last quarter. Company insiders own 8.40% of the company's stock.
Institutional Trading of Day One Biopharmaceuticals
Several hedge funds have recently added to or reduced their stakes in the business. Exchange Traded Concepts LLC increased its position in Day One Biopharmaceuticals by 19.6% during the 1st quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company's stock valued at $117,000 after purchasing an additional 2,407 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in Day One Biopharmaceuticals in the 1st quarter worth about $88,000. Pallas Capital Advisors LLC purchased a new position in Day One Biopharmaceuticals in the 1st quarter worth approximately $87,000. Hennion & Walsh Asset Management Inc. increased its holdings in Day One Biopharmaceuticals by 13.9% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 137,968 shares of the company's stock worth $1,094,000 after buying an additional 16,801 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Day One Biopharmaceuticals by 8.3% in the 1st quarter. Rhumbline Advisers now owns 81,844 shares of the company's stock worth $649,000 after purchasing an additional 6,291 shares during the period. 87.95% of the stock is owned by institutional investors.
Day One Biopharmaceuticals Company Profile
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Stories
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
